Skip to content
Tech News
← Back to articles

Exclusive: Race begins to trial Ebola drugs amid current outbreak

read original more articles
Why This Matters

The race to develop and trial experimental Ebola treatments and vaccines is crucial for addressing the current outbreak of the rare Ebola Bundibugyo virus, which has no approved therapies. Rapid testing and deployment of these treatments could significantly improve response efforts and save lives, highlighting the importance of swift innovation in infectious disease management for the tech and healthcare industries. This effort underscores the need for adaptable, fast-tracked clinical solutions in combating emerging viral threats.

Key Takeaways

The World Health Organization (WHO) declared an outbreak of Ebola in the Democratic Republic of the Congo (DRC) a public health emergency of international concern on 17 May.Credit: Jospin Mwisha/AFP via Getty

Scientists are racing to trial experimental treatments and potentially vaccines against a rare Ebola species that is spreading in the Democratic Republic of the Congo (DRC) and Uganda.

There are no approved treatments or vaccines against Ebola Bundibugyo virus, which has been linked to 336 suspected cases and 88 deaths, according to data from the US Centers for Disease Control and Prevention as of on 17 May.

Nature has learnt that a World Health Organization (WHO)-sponsored clinical trial of two experimental treatments for Ebola Bundibugyo virus disease is in the works, pending approval by the governments of DRC and Uganda. Health officials are also considering whether an approved vaccine for another species of Ebola virus could be trialled in the current outbreak.

“I think we’re in a really strong position to quickly launch trials,” says Amanda Rojek, a clinical researcher at the University of Oxford, UK, who is part of the treatments trial. “We’re working day and night at the moment.”

Investigational therapies

Rojek, who is part of a WHO effort to rapidly trial treatments against filoviruses, which includes Ebola and Marburg viruses, during outbreaks, says the trial will focus on two therapies.

One is the broad-acting antiviral called remdesivir, which is manufactured by Gilead Sciences in Foster City, California. The other is a treatment called MBP134, which is a mixture of two antibodies that recognize diverse Ebola viruses and was developed by Mapp Biopharmaceuticals in San Diego, California.

Remdesivir was trialled in a 2018–19 DRC outbreak of another species of Ebola virus called Zaire1, as well as against SARS-CoV-2 during the global pandemic, where its efficacy was modest. MBP134 was administered in a 2022 outbreak of the Sudan species of Ebola in Uganda, but this was done outside of a clinical trial under ‘compassionate use’ in which patients with a life-threatening disease can get access to investigational therapies. It was not possible to determine whether the drug worked or not.

Hopes rise for coronavirus drug remdesivir

... continue reading